Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions.
The use of angiotensin-converting enzyme inhibitors (captopril and enalapril) to control hypertension has increased in recent years. Despite extensive reports of hematologic, gastrointestinal, and cutaneous side effects, no specific incidence of oral mucosal lichenoid reactions caused by these drugs have been reported. It is the purpose of this article to present two case reports, bringing the attention of clinicians to oral mucosal lichenoid drug reactions in which these drugs may be implicated.
Firth
N A
NA
University of Melbourne, Victoria, Australia.
Reade
P C
PC
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D002216:Captopril / Q000009:adverse effects; D004656:Enalapril / Q000009:adverse effects; D005260:Female; D006801:Humans; D008010:Lichen Planus / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced*
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D002216:Captopril